Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Sumitomo Dainippon Pharma Co ( (JP:4506) ).
Sumitomo Pharma Co., Ltd. has entered into a co-promotion partnership with Janssen Pharmaceutical K.K. to market XEPLION and XEPLION TRI, long-acting antipsychotic medications for schizophrenia, in Japan. This collaboration aims to bolster Sumitomo Pharma’s portfolio in the Psychiatry & Neurology area, enhancing treatment options for schizophrenia patients, with minimal expected impact on the company’s financial results for fiscal year 2024.
More about Sumitomo Dainippon Pharma Co
Sumitomo Pharma Co., Ltd. operates in the pharmaceutical industry, focusing on the Psychiatry & Neurology sector in the Japanese market. They have developed and marketed treatments for schizophrenia, such as Latuda and LONASEN Tape, and aim to expand their influence in this area.
YTD Price Performance: 5.48%
Average Trading Volume: 3,866
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.4B
See more data about 4506 stock on TipRanks’ Stock Analysis page.
